+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

G

Actively Recruiting

This research is a global, multicenter, prospective observational registry studying patients with Pompe disease, including both late-onset LOPD and infantile-onset IOPD forms. It enrolls both untreated patients and those receiving approved therapies to better understand the long-term safety, real-world effectiveness, and quality of life impacts of treatments for Pompe disease. The study also aims to describe the natural history of untreated Pompe disease. Participants include groups receiving different enzyme replacement therapies such as Cipaglucosidase alfa with Miglustat, other approved ERTs like Alglucosidase alfa or Avalglucosidase alfa, as well as untreated individuals who are not on any medical therapy for Pompe disease. No experimental treatments are given as this is an observational study tracking real-world treatment use and outcomes. During the study, participant data on adverse events, treatment effectiveness, quality of life, and patient-reported outcomes will be collected over a period of at least five years. Researchers will monitor safety through the frequency of adverse events and serious adverse events. Participants health and treatment impacts will be regularly evaluated to provide long-term insights into Pompe disease management and outcomes.

All AgesAll Genders
41 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of N-acetyl-L-leucine IB1001 compared to standard care for patients aged 4 years and older diagnosed with Niemann-Pick disease type C NPC. This is a pivotal, randomized, double-blind, placebo-controlled, multi-center study designed to provide important information on this treatments impact on NPC symptoms. The study includes a crossover design where participants receive both the study drug and placebo during separate periods. Participants will take N-acetyl-L-leucine or a placebo orally as granules suspended in water, orange juice, or almond milk. Patients aged 13 and older will receive a total daily dose of 4 grams divided into three doses, while those under 13 will receive weight-based dosing. The study consists of a baseline period followed by two treatment periods of about 12 weeks each, where participants switch from one treatment to the other. After completing the parent study, some patients may join an open-label extension phase providing up to three years of treatment. During the trial, participants will undergo assessments at several points, including before and after each treatment period. These include scales measuring ataxia severity, functional ability, disability, clinical global impressions from physicians, caregivers, and patients, and quality of life questionnaires. Researchers will monitor adherence and safety throughout the study. The trial continues until December 2030, with careful evaluation of the primary outcomes after each treatment phase and ongoing follow-up for those in the extension phase.

Age: 4Years +All GendersPhase 3
14 locations
E

Actively Recruiting

Researchers are conducting an 18-month Phase 3 clinical trial to study the safety and efficacy of oral nizubaglustat AZ-3102 in children and young people aged 4 years and older with late-infantile and juvenile forms of Niemann-Pick Type C NPC disease. This randomized, double-blind, placebo-controlled study aims to compare the effects of nizubaglustat against placebo on ataxic symptoms and other disease manifestations in this rare neurological condition. Participants will receive once-daily oral dispersible tablets of either nizubaglustat or a matching placebo over 18 months. The study examines the drugs pharmacokinetics and pharmacodynamics, along with its safety and tolerability. The trial is conducted at multiple centers and includes a parallel study design where participants are randomly assigned to one of the two groups. Throughout the study, participants will undergo regular assessments including the Scale for the Assessment and Rating of Ataxia SARA, Vineland Adaptive Behavior Scale, Penetration-Aspiration Scale, and several other evaluations at baseline and at months 6, 12, and 18. Researchers will also monitor seizure frequency and drug plasma levels, as well as record any adverse effects. The primary outcomes focus on changes in ataxia scores over the 18-month period to evaluate the treatments impact.

Age: 4Years +All GendersPhase 3
34 locations
P

Actively Recruiting

Researchers are studying the safety and effects of oral nizubaglustat AZ-3102 in children aged 4 years and older with late-infantile or juvenile forms of Niemann-Pick type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. This Phase 3 study is double-blinded, randomized, placebo-controlled, and conducted at multiple centers. It uses a Master Protocol Research Program with different subprotocols for each disease type to evaluate treatment outcomes. Participants are randomly assigned in a 21 ratio to receive either oral nizubaglustat or a matching placebo. The study lasts 18 months and includes separate subprotocols for Niemann-Pick type C disease and for GM1 or GM2 gangliosidosis. Each subprotocol may have additional eligibility criteria and specific safety and efficacy assessments. During the study, participants undergo evaluations defined in their disease-specific subprotocols. Researchers monitor safety and efficacy throughout the 18-month period, tracking the number of participants assigned to each subprotocol. The study aims to gather detailed information on the treatments impact over this timeframe, with continuous monitoring to assess participant health and responses.

Age: 4Years +All GendersPhase 3
39 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, pharmacokinetics PK, pharmacodynamics PD, and immune response to the treatment combination of cipaglucosidase alfa and miglustat in children with infantile-onset Pompe disease IOPD. This Phase 3, open-label, multicenter study includes both children who have previously received enzyme replacement therapy ERT and those who have not. The study focuses on pediatric subjects from birth up to 18 years old who have this rare genetic condition characterized by heart muscle thickening and muscle weakness. The study has two groups one includes children aged 6 months to under 18 years who have experienced clinical decline despite prior ERT, and the other includes infants younger than 6 months who have not received ERT before. Participants will receive intravenous infusions of cipaglucosidase alfa, a biological treatment, along with oral capsules of miglustat. The study also has a long-term extension phase for participants who benefit from the primary 104-week treatment period without major safety concerns. During the study, children will be monitored for infusion-related reactions and other safety measures over 104 weeks. Evaluations include physical tests like the six-minute walk test for older children, genetic confirmation of IOPD, and assessments of heart and muscle function. Researchers will track immune responses, drug levels in the body, and overall health status. The study aims to gather detailed data on how the treatment affects disease progression and safety in this young population.

Age: 0 - 17YearsAll GendersPhase 3
14 locations
P

Actively Recruiting

Researchers are studying the safety, pharmacodynamics, and initial clinical effects of S-606001 in adults with late-onset Pompe disease LOPD. This study focuses on adding S-606001 to the existing enzyme replacement therapy ERT to evaluate its impact over time. Participants are randomly assigned to receive either a low dose or high dose of S-606001, or a matching placebo, taken orally twice daily after meals for 52 weeks. The study is double-blind, meaning neither participants nor researchers know who receives which dose or placebo during the trial. Throughout the 52 weeks, participants will be evaluated using lung function tests, 6-minute walk tests, muscle strength assessments, and patient-reported questionnaires on fatigue, pain, and physical function. Safety monitoring includes tracking adverse events and blood tests. Changes from baseline in forced vital capacity %FVC at week 52 is the primary outcome measured.

Age: 18Years +All GendersPhase 2
28 locations